# Consolidated Results First Half of the FY Ending March 31, 2015 (Interim FY2014)

- 1. Overview
- 2. Financial Position
- 3. Segment Information

November 10, 2014

Hiromichi Oono

Member of the Board and
Corporate Vice President
Ajinomoto Co., Inc.

### **МІНОМОТО.** 1. (1) Overview of Results

(¥ Billion)

	Interim Interim FY2014 FY2013			YoY Change		FY2014 (Revised Progress Forecast)		July-Sept.	YoY Ch	nange
	(A)	1 12010	Amount	%	(B)	(A)/(B)	2014	2013	Amount	%
Net sales	467.6	468.9	-1.3	-0%	1,008.0	46%	240.0	235.2	4.8	2%
Domestic Food Products	147.3	144.3	3.0	2%	312.3	47%	76.3	74.1	2.2	3%
Overseas Food Products	153.1	144.1	9.1	6%	322.2	48%	78.8	72.7	6.1	8%
Bioscience Products & Fine Chemicals	108.3	111.6	-3.4	-3%	238.4	45%	55.1	56.6	-1.5	-3%
Pharmaceuticals	18.8	27.9	-9.1	-33%	40.9	46%	9.4	11.1	-1.8	-16%
Other Business	40.1	41.0	-0.9	-2%	94.2	43%	20.4	20.6	-0.2	-1%
Operating income	28.6	29.7	-1.2	-4%	70.0	41%	15.3	14.5	0.8	5%
Domestic Food Products	10.1	11.4	-1.3	-11%	28.8	35%	5.1	5.2	-0.1	-2%
Overseas Food Products	16.4	12.8	3.6	28%	29.4	56%	8.7	6.7	2.0	30%
Bioscience Products & Fine Chemicals	2.6	3.9	-1.3	-34%	9.7	27%	1.8	1.4	0.4	31%
Pharmaceuticals	0.2	1.5	-1.3	-85%	2.3	10%	0.0	1.1	-1.1	-96%
Other Business	-0.8	0.2	-0.9	-560%	-0.2	375%	-0.4	0.1	-0.5	-393%
Ordinary income	31.9	33.1	-1.2	-4%	75.0	43%	16.4	15.9	0.5	3%
Net income	20.7	22.3	-1.6	-7%	44.0	47%	9.8	10.4	-0.6	-6%
Exchange rate JPY/USD	103.01	98.86			100.0					
JPY/EUR	138.90	129.98			130.0					

#### Notes

- 1, July-Sept. results are the difference between Apr.-Sept. results and Apr.-June results (for this and all following slides).
- 2. From FY2014, sales promotion discounts, etc. are deducted from net sales rather than being recorded in selling, general and administrative expenses. In addition, under this accounting treatment the estimated amount is recorded when sales are recorded rather than when the amount to be paid is determined.
- 3. Results for FY2013 have been restated to reflect the above changes (for this and all following slides).



#### **✓JINOMOTO.** 1. (2) Comments on Results for Interim FY2014

Net sales remained almost at the level of the previous first half year because of growth in sales of Overseas Food Products and Domestic Food Products, despite impact of spin-off of infusion and dialysis business units in Pharmaceuticals and decrease in sales of feed-use amino acids, etc.

Operating income decreased overall due to lower income in every segment except Overseas Food Products, where income increased substantially.

However, second quarter (July-Sept.) sales and income both increased compared with the same period of the previous year.

#### Net sales / Operating income

Interim	Progress	YoY		July-Sept.	YoY
FY2014	riogiess	Change		2014	Change
467.6	46%	-0%	Net sales	240.0	2%
309.7	-	-1%	Cost of sales	159.2	1%
129.3	-	3%	SG&A	65.5	5%
28.6	41%	-4%	Operating income	15.3	5%

1. Impact of exchange rate (YoY)

**Exchange rate for currency translation** 

1H: Sales ¥3.8 billion; operating income -¥0.1 billion Q2: Sales ¥4.6 billion; operating income ¥0.4 billion

Exchange rate for trade of main overseas subsidiaries

1H: Sales approx. ¥1.0 billion; operating income approx. ¥1.0 billion

Q2: Sales approx. ¥0.0 billion; operating income approx. ¥0.0 billion


- 2. Impact of raw material & fuel prices (YoY)
- 1H: Fermentation raw materials and fuel prices approx. ¥4.8 billion Domestic food products raw materials approx. -¥0.6 billion
- Q2: Fermentation raw materials and fuel prices approx. ¥3.8 billion Domestic food products raw materials approx. -¥0.3 billion
- 3. Cost reductions (YoY)
- 1H: Domestic food products approx. ¥1.3 billion; Pharmaceuticals approx. ¥0.6 billion
- Q2: Domestic food products approx. ¥0.7 billion; Pharmaceuticals approx. ¥0.2 billion

## **JINOMOTO**. 1. (3) Comments on Results for Interim FY2014

Ordin	ary inco	ome			(¥ Billion)	
Interim FY2014	Progress	YoY Change		July-Sept. 2014	YoY Change	< Interim FY2014 > ( )= YoY change None
3.3	-	-1%	Non-operating income (net)	1.2	-19%	< Q2-FY2014 > ( )=YoY change
31.9	43%	-4%	Ordinary income	16.4	3%	None

1	Net income < Interim FY2014 > ( )= YoY change											
ľ							*1 Gain on sale of shares in affiliated companies					
ı	nterim	Drogross	YoY		July-Sept.	YoY	¥0.0 billion (¥2.3 billion decrease)					
F	Y2014	Progress	Change		2014	Change	*1 Insurance income					
	0.9	-	-76%	Extraordinary gains *1	0.2	-90%	¥0.0 billion (¥1.2 billion decrease)					
	1.3	-	-34%	Extraordinary losses *2	2 0.9	-8%	*1 Gain on bad debts recovered					
	6.6	-	-23%	Income taxes, etc.	4.1	-18%	¥0.6 billion (¥0.6 billion increase)					
	4.1	-	7%	Minority interests	1.9	-2%	*2 Loss on liquidation of subsidiaries					
	20.7	47%	-7%	Net income	9.8	-6%	¥0.0 billion (¥0.7 billion decrease)					

#### **JINOMOTO**. 2. Financial Position



¥18.6 billion increase in total assets from March 31, 2014
\*Increase in yen values of the balance sheets of overseas subsidiaries after currency translation

#### **Cash Flow**

(¥ Billion)

	Sept. 2014	Sept. 2013	Change
1. CF from operating activities	56.8	19.6	37.2
2. CF from investing activities	-22.8	-37.4	14.6
3. CF from financing activities	-14.5	-22.7	8.1
4. Cash and cash equivalents	153.8	142.5	11.2
FCF(1+2)	34.1	-17.8	51.9

\*Cash out is shown with -.

Capital expenditures	-22.5	-27.2	4.8
Depreciation and amortization	21.1	22.5	-1.4

Interest-bearing Debt


(¥ Billion)

<Reference>

Sept. 2014	Mar. 2014	Change	Sept. 2013
137.1	143.0	-5.8	136.3



### **JINOMOTO.** 3. (1) Change by Business Segment



#### **JINOMOTO**. 3. (2) Domestic Food Products

					<refer< th=""><th>ence&gt;</th><th></th></refer<>	ence>	
Interim FY2014	Progress	Interim FY2013	YoY Change		July-Sept. 2014	July-Sept. 2013	YoY Change
147.3	47%	144.3	3.0	Net sales	76.3	74.1	2.2
92.7	-	92.2	0.5	*1 Seasonings & processed foods	48.4	47.3	1.1
54.6	-	52.1	2.5	*2 Frozen foods	27.9	26.8	1.1
10.1	35%	11.4	-1.3	*3 Operating income	5.1	5.2	-0.1
11.6	-	12.1	-0.5	Seasonings & processed foods	6.0	5.6	0.3
2.5	-	2.7	-0.2	Frozen foods	1.2	1.4	-0.2
-4.0	47%	-3.5	-0.5	Shared companywide expenses	-2.1	-1.8	-0.3

<sup>\*3</sup> Income decreased overall due to increased marketing expenses to stimulate the market in seasonings & processed foods, impact of higher raw material prices for frozen foods and increased marketing expenses, etc.



<sup>\*1</sup> Impact of increase in the consumption tax ended in the first quarter. Increase in overall sales due to increase in sales resulting from measures to stimulate the market for home-use products in the second quarter and growth in functional food products, etc. for restaurant- and institutional- use.

<sup>\*2</sup> Increase in overall sales due to slight increase in sales in Japan and growth in sales overseas, mainly in North America.

### **JINOMOTO**. 3. (3) Overseas Food Products

(¥ Billion)

					<refer< th=""><th>ence&gt;</th><th></th></refer<>	ence>	
Interim FY2014	Progress	Interim FY2013	YoY Change		July-Sept. 2014	July-Sept. 2013	YoY Change
153.1	48%	144.1	9.1	Net sales	78.8	72.7	6.1
128.0	47%	118.9	9.1	*1 Consumer foods	66.1	60.8	5.3
25.1	50%	25.2	-0.0	Umami seasonings for processed food mfrs.	12.7	12.0	0.8
16.4	58%	12.8	3.6	*3 Operating income	8.7	6.7	2.0
-5.4	47%	-4.6	-0.8	Shared companywide expenses	-2.8	-2.4	-0.4

[Effect of currency translation] Q2: Net sales +¥2.3 billion; operating income +¥0.4 billion 1H: Net sales +¥0.1 billion; operating income -¥0.2 billion

Reference: Consumer foods +¥3.6 billion; umami seasonings for processed food mfrs. +¥0.6 billion



<sup>\*1</sup> Increase in sales because of higher sales volume of umami seasoning *AJI-NO-MOTO* and flavor seasonings, etc., despite negative effect of currency translation.

<sup>\*2</sup> Sales remained at level of previous interim period because of drop in unit price of nucleotides, etc., despite positive effect of currency translation.

<sup>\*3</sup> Increase in income as increase in sales volume of consumer foods and cost reduction of umami seasonings for processed food mfrs., etc. offset negative effect of currency translation.

#### **JINOMOTO**. 3. (4) Bioscience Products & Fine Chemicals

					<refer< th=""><th>ence&gt;</th><th>(¥ Billion)</th></refer<>	ence>	(¥ Billion)
Interim	Progress	Interim	YoY		July-Sept.	July-Sept.	YoY
FY2014		FY2013	Change		2014	2013	Change
108.3	45%	111.6	-3.4	Net sales	55.1	56.6	-1.5
43.9	43%	47.5	-3.5 <sup>°</sup>	1 Feed-use amino acids	22.9	23.8	-0.9
41.1	-	39.2	1.9	2 Amino acids	20.6	20.2	2 0.4
21.7	-	22.3	-0.6	Specialty chemicals	11.0	11.2	-0.2
2.6	27%	3.9	-1.3	<sup>4</sup> Operating income	1.8	1.4	0.4
-1.1	-27%	0.9	-1.9	Feed-use amino acids	0.2	0.1	0.1
2.8	-	2.1	0.7	Amino acids	1.4	0.9	0.5
5.5	-	5.1	0.4	Specialty chemicals	2.7	2.6	0.1
-3.7	48%	-3.3	-0.4	Shared companywide expenses	-1.9	-1.7	-0.2

[Effect of currency translation] Q2: Net sales +\(\frac{4}{1.9}\) billion; operating income -\(\frac{4}{0.0}\) billion

1H: Net sales +\(\frac{4}{3.4}\) billion; operating income +\(\frac{4}{0.1}\) billion

Reference: Within amino acids, amino acids for pharmaceuticals and foods +¥0.7 billion; pharmaceutical custom manufacturing +¥0.1 billion; sweeteners -¥0.0 billion

<sup>\*1</sup> Decrease in sales due to significant decrease in Lysine unit price, despite positive effect of currency translation.

<sup>\*2</sup> Amino acids for pharmaceuticals and foods +¥0.5 billion; pharmaceutical custom manufacturing +¥0.9 billion; sweeteners +¥0.6 billion.

<sup>\*3</sup> Decrease in sales due to decrease in retail sales of cosmetics due to pullback from last-minute surge in demand at the previous fiscal year end in connection with an increase in the consumption tax and decrease in sales of chemicals other than electronic materials.

<sup>\*4</sup> Decrease in income because higher income of amino acids for pharmaceuticals and foods and specialty chemicals, etc., did not offset lower income of feed-use amino acids, etc.

### **JINOMOTO**. 3. (5) Pharmaceuticals

						<refer< th=""><th>ence&gt;</th><th>(¥ Billion)</th></refer<>	ence>	(¥ Billion)
Interim FY2014	Progress	Interim FY2013	YoY Change			July-Sept. 2014	July-Sept. 2013	YoY Change
18.8	43%	27.9	-9.1	*1	Net sales	9.4	11.1	-1.8
0.2	7%	1.5	-1.3	*2	Operating income	0.0	1.1	-1.1
-0.7	42%	-0.8	0.1	Shai	red companywide expenses	-0.3	-0.3	-0.0

Sales based on AJINOMOTO PHARMACEUTICALS CO., LTD. estimated drug prices (% = YoY change):

LIVACT	¥6.8 billion	(-10%)	ELENTAL	¥3.8 billion	(-1%)
ATELEC	¥6.1 billion	(-19%)	ACTONEL	¥4.5 billion	(-12%)
FASTIC	¥0.7 billion	(-26%)			

<sup>\*2</sup> Decrease in income because improved operational efficiency and increased royalty income did not cover the impact of decreases in sales of self-distributed products and products sold through business tie-ups.



<sup>\*1</sup> Decrease in sales of both domestic products and products sold through business tie-ups due to the impact of NHI drug price revisions and generics, in addition to the impact of spin-off of infusion and dialysis business units (approx. ¥4.9 billion) in July 2013.

### **JINOMOTO**. 3. (6) Other Business

(¥ Billion)

					<refer< th=""><th>ence&gt;</th><th></th></refer<>	ence>	
Interim FY2014	Progress	Interim FY2013	YoY Change		July-Sept. 2014	July-Sept. 2013	YoY Change
40.1	44%	41.0	-0.9	*1 Net sales	20.4	20.6	-0.2
1.0	-	1.1	-0.1	Edible oils & coffee products	0.5	0.6	-0.1
-0.8	323%	0.2	-0.9	*2 Operating income	-0.4	0.1	-0.5
0.9	-	1.1	-0.2	Edible oils & coffee products	0.5	0.5	-0.1
-1.7	46%	-1.5	-0.2	Shared companywide expenses	-0.8	-0.8	-0.1

<sup>\*1</sup> Decrease in sales mainly due to a decrease in sales of logistics business, etc.

<sup>\*2</sup> Decrease in income due to lower income in logistics business, etc., despite higher income in wellness business.



## 3. (7) Net Sales by Business & Geographical Area

Upper row: Interim FY2014; lower row: Interim FY2013.

Figures in parentheses represent YoY change.

(¥ Billion)

	Japa	ın	Asia		Americas		Europe		Total	
Domestic Food	135.5	(0.7)	2.9	(0.0)	6.9	(1.2)	1.9	(1.1)	147.3	(3.0)
Products	134.9		2.9		5.7		0.8		144.3	
Overseas Food	4.6	(0.1)	104.1	(5.6)	30.1	(3.3)	14.3	(0.0)	153.1	(9.1)
Products	4.6		98.5		26.8		14.2		144.1	
<b>Bioscience Products</b>	30.7	(-1.4)	8.9	(-0.1)	35.0	(-0.6)	33.7	(-1.2)	108.3	(-3.4)
& Fine Chemicals	32.1		9.0		35.5		35.0		111.6	
Pharmaceuticals	18.8	(-9.1)							18.8	(-9.1)
- Harmaceuticals	27.9								27.9	
Other Business	35.7	(-0.5)	4.4	(-0.4)	0.1	(0.0)			40.1	(-0.9)
Other Business	36.2		4.8		0.0				41.0	
Total	225.3	(-10.3)	120.3	(5.1)	72.0	(4.0)	49.9	(-0.1)	467.6	(-1.3)
i Otai	235.6		115.2	-	68.1		50.0	·	468.9	•





## 3. (8) Operating Income by Business & Geographical Area

Upper row: Interim FY2014; lower row: Interim FY2013.

Figures in parentheses represent YoY change.

(¥ Billion)

	Japa	an	Asi	Asia		Americas		Europe		Other *		Total	
Domestic Food	12.2	(-0.8)	0.9	(-0.2)	0.7	(0.0)	0.3	(0.1)	-3.9	(-0.4)	10.1	(-1.3)	
Products	13.0		1.1		0.7		0.2		-3.6		11.4		
Overseas Food	-0.7	(0.3)	18.3	(3.2)	4.6	(0.5)	-0.3	(0.1)	-5.5	(-0.5)	16.4	(3.6)	
Products	-1.0		15.1		4.1		-0.3		-5.1		12.8		
Bioscience Products & Fine	6.2	(0.4)	-0.3	(-0.7)	0.2	(0.2)	0.3	(-1.1)	-3.8	(-0.1)	2.6	(-1.3)	
Chemicals	5.8		0.4		0.0		1.4		-3.7		3.9		
Pharmaceuticals	0.9	(-1.4)							-0.7	(0.1)	0.2	(-1.3)	
	2.3								-0.8		1.5		
Other Business	0.6	(-0.6)	0.5	-0.2	0.0	(0.0)	-0.0	(-0.0)	-1.8	(-0.1)	-0.8	(-0.9)	
Other Dusiness	1.2		0.7		0.0		-0.0		-1.7		0.2		
Shared companywide	-7.3	(-0.1)	-4.5	(-0.5)	-2.3	(-0.2)	-1.6	(-0.1)	15.8	(0.9)	0.0	(0.0)	
expenses, etc.*	-7.2		-4.0		-2.1		-1.6		14.9		0.0		
Total	11.9	(-2.3)	14.9	(1.7)	3.1	(0.5)	-1.4	(-1.0)			28.6	(-1.2)	
Total	14.2		13.3	` ′	2.7	` ′	-0.3				29.7		

<sup>\*</sup> Includes shared companywide expenses and unrealized gains and losses not reflected in any geographical area, etc.





## 3. (9) Comments on Operating Income by Business & Geographical Area

#### Interim FY2014 Change Compared with Same Period of Previous Year

1. Overseas Food Products

(¥ Billion)

[YoY change]
Japan +0.3; Asia +3.2; Americas +0.5; Europe +0.1; Other\* -0.5; Total +3.6

Asia: Increase due to higher sales of consumer foods products, etc., despite negative effect of currency translation

2. Bioscience Products & Fine Chemicals

[YoY change] (¥ Billion)


Japan +0.4; Asia -0.7; Americas +0.2; Europe -1.1; Other\* -0.1; Total -1.3

Europe: Decrease due to feed-use amino acids, etc.

<sup>\*</sup> Includes shared companywide expenses and unrealized gains and losses not reflected in any geographical area, etc.



## (Reference) Interim FY2014 Trends in Overseas Consumer Food Products



#### Interim FY2014 Overseas Consumer Food Products Sales in Main Countries

> Thailand: approx. THB 15.9 billion

(+3% YoY, +2% on yen basis)

> Indonesia: approx. IDR 1,771.2 billion

(+16% YoY, +6% on yen basis)

(Revision FY2014/Q1) approx. IDR 836.1 billion (+18% YoY, +2% on yen basis)

> Brazil: approx. BRL 0.34 billion

(+13% YoY, +14% on yen basis)


> Vietnam: approx. VND 2,891.9 billion

(+8% YoY, +13% on yen basis)

> Philippines: approx. PHP 2.7 billion

(+10% YoY, +11% on yen basis)

### **JINOMOTO**. (Reference) Feed-Use Lysine Market Price and CBOT Spread\* Trend





## 

- ➤ Forward-looking statements, such as business performance forecasts, made in these materials are based on management's estimates, assumptions and projections at the time of publication and do not represent a commitment from Ajinomoto Co., Inc. that they will be achieved. A number of factors could cause actual results to differ materially from expectations.
- ➤ Unaudited figures are included in these materials for reference.
- ➤ Amounts presented in these materials are rounded off.